<DOC>
	<DOCNO>NCT02522767</DOCNO>
	<brief_summary>The purpose trial investigate safety efficacy mesalamine induction clinical endoscopic remission subject active , mild moderate UC . Subject receive 4 g extend release granule ( sachet ) daily .</brief_summary>
	<brief_title>Mesalamine 4 g Sachet Induction Remission Active , Mild Moderate Ulcerative Colitis ( UC )</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Male female subject age 18 75 year Mild moderate UC Disease limit proctitis &lt; 15 cm Short bowel syndrome Prior colon resection surgery History severe/fulminant UC Evidence form inflammatory bowel disease Infectious disease ( include human immunodeficiency virus [ HIV ] , hepatitis B virus [ HBV ] , hepatitis C virus [ HCV ] ) Intolerant allergic aspirin salicylate derivative Use rectal formulation ( 5aminosalicylic acid [ 5ASA ] , steroid ) within â‰¤7 day Women pregnant nursing History know malignancy History bleeding disorder , active gastric active duodenal ulcer , autoimmune disease , mental/emotional disorder , would interfere participation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>